EU advisors recommend Avastin for refractory ovarian cancer
- The Committee for Medicinal Products for Human Use (CMHP) has recommended Avastin (bevacizumab) combined with chemotherapy for treatment of ovarian cancer that is resistant to platinum-containing chemotherapy.
- The recommendation is based on positive data from a phase III trial.
- Avastin is widely used as part of treatment regimens for various cancers, including breast, colorectal, non-small cell lung and kidney cancers.
The positive recommendation for a combination regimen that includes Avastin is based on data that showed that adding on Avastin to chemotherapy decreased risk of disease progression or death by 62%. Avastin, which is widely used as part of many different types of cancer treatment regimens, is a top-selling oncology drug that grossed $6.74 billion in 2013.